Share on StockTwits

GlaxoSmithKline plc (LON:GSK)‘s stock had its “market perform” rating reaffirmed by equities research analysts at Sanford C. Bernstein in a research note issued to investors on Thursday. They currently have a GBX 1,571 ($26.07) target price on the stock. Sanford C. Bernstein’s price objective would suggest a potential upside of 7.09% from the stock’s previous close.

A number of other firms have also recently commented on GSK. Analysts at Deutsche Bank reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Thursday, August 21st. They now have a GBX 1,500 ($24.89) price target on the stock. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Wednesday, August 20th. They now have a GBX 1,385 ($22.98) price target on the stock. Finally, analysts at Credit Suisse reiterated an “underperform” rating on shares of GlaxoSmithKline plc in a research note on Friday, August 15th. They now have a GBX 1,475 ($24.48) price target on the stock. Four analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of GBX 1,630.42 ($27.06).

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1475.00 on Thursday. GlaxoSmithKline plc has a 1-year low of GBX 1200.668 and a 1-year high of GBX 1706.00. The stock has a 50-day moving average of GBX 1446. and a 200-day moving average of GBX 1570.81. The company’s market cap is £70.859 billion.

The company also recently announced a dividend, which is scheduled for Thursday, October 2nd. Shareholders of record on Wednesday, August 6th will be paid a dividend of GBX 19 ($0.32) per share. This represents a dividend yield of 1.28%. The ex-dividend date is Wednesday, August 6th.

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.